Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Stanford University and VinBrain – To design a state-of-the-art AI-enabled platform to advance medical diagnosis and treatments

Vingroup

HANOI, VIETNAM – Media OutReach – 14 February 2023 - On Jan 12 (PST Time), Mr. Steven Truong, CEO of VinBrain, attended the Data Use Agreement Signing Ceremony at the Stanford campus (Palo Alto, USA) organized by Stanford Center for Artificial Intelligence for Medical and Imaging (AIMI). This ceremony occurred with AIMI’s Director, Professor Curtis Langlotz along with other distinguished AIMI leaders, and the VinBrain leadership team. To design a state-of-the-art AI-enabled platform for more accurate diagnosis and treatments, a tremendous amount of geographically distributed data, medical images, and patient medical records are required for system training. The DUA grants Stanford University and VinBrain the collaborative power to improve efficiency in radiology reports and advance AI in healthcare by sharing relevant de-identified data for model training and testing, while tackling complexity, ambiguity, and limitations in medical image interpretation. Starting with 240,000 anonymized medical images and report pairs provided by Stanford through this DUA,VinBrain will work to improve the accuracy of the RadGraph method through a research collaboration with Stanford to extract clinical entities and relation annotations from a large dataset of full-text radiology reports. With this strong support from Stanford, VinBrain aims to raise the bar for research on AI solutions by collaborating beyond Vietnam to improve product quality, meanwhile, continuing to add and develop the most massive data source in Vietnam to date, with more than 2.3 million images being analyzed through the DrAid™ platform so far. Mr. Steven Truong affirmed: "VinBrain always strictly adheres to data security regulations according to USA standards." He also emphasized that Stanford sharing data with VinBrain demonstrates Stanford's absolute trust in VinBrain's commitment to data privacy and security. The DUA signed with Stanford University is not an overnight result but a long journey of 3+ years of collaboration. This collaboration has produced many research projects together that have achieved desirable clinical outcomes. Professor Curtis Langlotz, Director of the Center for Artificial Intelligence in Medicine and Stanford University also expressed his enthusiasms, “I remember the first time I met Steven at RSNA Spotlight organized by Stanford near San Francisco Airport. It was the beginning of this wonderful relationship that developed over time. We appreciate VinBrain’s leadership in research and the capabilities that they have. The speed of work is incredible, and I also appreciate the collaborative spirit of VinBrain.” He added, “I know that we've done a lot, but there's still a lot more to do. I look forward to continued collaborations. I'm glad we sat down together to sign this Agreement." This Agreement promises to comprehensively expand cooperation in the next areas of development, strengthen the relationship between VinBrain and the world’s leading University, and take VinBrain further in the research of AI-developed solutions for worldwide patients. About RadGraph: a novel method introduced by Prof. Pranav Rajpurkar (Harvard University) and Prof. Curtis Langlotz at Stanford. This collaboration works between Stanford University and VinBrain to address complexity, ambiguity, and limitations for interpreting medical images. About DrAid™: a platform of comprehensive artificial intelligence (AI) doctor assistant software developed by VinBrain to assist medical teams and doctors in diagnosing heart, lung, liver, and bone diseases based on digital medical images. The platform is evaluated to have superior efficiency compared to traditional methods in observing and analyzing medical images, helping in reducing overload and improving early detection in diagnosis. DrAid Radiology V1: An AI-enabled triage and notification software designed to aid the clinical assessment of adult Chest X-ray cases with features suggestive of pneumothorax. This software is FDA 510(K) cleared and apt for the US market. DrAid™ Appliance: an AI-enabled system to classify an adult Chest X-ray between normal and nearly 60 abnormal findings with higher-than-average quality standards of primary care physicians About VinBrain: VinBrain is a leading AI healthcare products company, funded by Vingroup, the largest conglomerate by market capitalization in Vietnam. Its mission is to infuse AI and IoT to improve people’s lives and productivity. Contact Details Media Contact v.chidqd1@vingroup.net Company Website https://vinbrain.net

February 14, 2023 10:30 AM Eastern Standard Time

Image

Acurx is Setting a High Bar for New Treatments in C. diff

Acurx Pharmaceuticals Inc

A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23 Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and recurrent infection. Primary C. diff is defined as the first episode of C. diff, while recurrent C. diff refers to the second or additional episodes following the primary infection. Re-infection occurs in up to 35% of individuals, with the risk of recurrence increasing with each episode. “Recurrence is the key cause of C. diff mortality and the principal contributor of C. diff’s more than two billion dollars in annual cost to the U.S. healthcare system,“ says David Luci, CEO of Acurx Pharmaceuticals ( Nasdaq; ACXP ), which is currently in Phase 2 clinical trials with a drug candidate that is showing high promise in curing C. diff infections in patients with primary C. diff or recurrent C. diff and, at the same time, preventing recurrence. In a Phase 2a study of the company’s C. diff candidate, called ibezapolstat, all ten patients enrolled were clinically cured of infection within two days of the end of treatment with no recurrence of C. diff at the 28-day follow-up visit. The positive clinical and safety results coupled with the beneficial effects on the gut microbiome resulted in the early termination of the study, and provided the first clinical hint of ibezapolstat’s potential superiority over vancomycin based on historical data. A 64-patient Phase 2b study is currently enrolling patients to further assess the efficacy and safety of ibezapolstat and its effects on the gut microbiome compared to vancomycin. The study will evaluate the comparative effects of ibezapolstat on clinical cure and sustained clinical cure (defined as clinical cure at the end of treatment visit and no recurrence within 28 days). It is expected that study enrollment will complete in 1Q 2023, with the release of interim results planned for 2Q 2023. Costly, Age Indifferent Infection with High Death Rate C. diff affects individuals of any age and is associated with significant and troublesome symptoms and mortality. Over the past decades, there has been a rapid increase in the incidence of community-acquired infection. C. diff has a profound economic impact on the healthcare system and patients due to recurrences, hospitalization, prolonged length of stay, and the cost of treatment which amount to roughly $2.8 billion dollars annually in the U.S—not to mention indirect societal costs such as loss of paid employment, and family disruptions. Vacnomycin has been the gold-standard antibiotic for treating C. diff and many other life-threatening infections since its introduction in 1965. “It’s a great drug. It has lasted roughly six decades as the go-to therapy for C. diff with very little competition”, notes Mr. Luci. “But its growing weakness, especially in preventing re-infection, has left a grizzly trail of serious sickness and a death rate of about 20,000 annually in the U.S. alone.” Clinical data collected over the years indicates that a typical new antibiotic has a peak efficacy of about five years and thereafter the process of antimicrobial resistance begins to set in —"a process by which bacteria learn to identify an antibiotic as a medicine and then find a way to morph their properties to avoid being killed by it,” explains Mr. Luci. “That’s why most antibiotics become less and less effective over time.” With today’s approved therapies, the estimated C. diff recurrence rate is around 20% after the initial treatment, increasing to 60% after multiple recurrences. Ibezapolstat - Gentle on Gut Flora Whilst Targeting Drug-Resistant Disease-Causing Bacteria The gut microbiome (also called gut flora) consists of trillions of microorganisms – such as bacteria and viruses – living inside the digestive tract. These microbes play an essential role in health, helping to break down food, absorb nutrients, and to protect against disease-causing microorganisms. Research has shown that changes in the composition and diversity of gut microbiomes can dramatically affect physical and mental well-being. A recently published Phase 1 study of Ibezapolstat in 10 healthy volunteers demonstrated that that Acrux’s C. diff candidate was effective against C. diff and caused changes in the structure and behavior of disease-causing bacteria, but not healthy bacteria. The results suggest that ibezapolstat is associated with a lower risk of C. diff recurrence than vancomycin. Furthermore, ibezapolstat did not adversely affect the gut microbiome, whilst vancomycin had undesirable effects on the gut microbiome and was ineffectual against drug-resistant bacteria. Current data would suggest that Ibezapolstat seems to be on a solid trajectory to become a first-line treatment for C. diff infection, given its ability to affect a total reduction in recurrence rates, would could lead to improvements in morbidity and mortality and a significant savings in healthcare and societal costs. This is in stark contrast to the failure of Pfizer ’s (NYSE: PFE) vaccine candidate PF-06425090 and the antibiotics cadazolid (investigated by Johnson & Johnson (NYSE: JNJ)) and surotomycin (investigated by Merck & Co (NYSE: MRK)) to meet their primary outcomes. More recently, in September 2022, Summit Therapeutics (Nasdaq: SMMT) decided to furlough development of ridinilazole for pediatric C. diff, and in January of this year, Finch Therapeutics Group (Nasdaq: FNCH) ended its development work on a fecal transplant technology for recurrent C. diff. Click here for more information about Acurx (ACXP) About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Featured Photo by Edward Jenner on Pexels Contact Details David P. Luci, President & CEO davidluci@acurxpharma.com

February 14, 2023 08:01 AM Eastern Standard Time

Image

IMA Financial Group Builds Industry-Leading Digital Risk Practice

IMA Financial

IMA Financial Group today announced that Senior Vice President, Director of Innovation & Strategy Garrett Droege will lead IMA’s Digital Risk Practice, launched in 2022 to study the inherent risks of emerging technology such as Web3, blockchain, crypto, decentralized finance and more. A recognized digital risk expert, Droege led the launch of IMA Web3Labs, the metaverse’s first insurance and risk management R&D facility, in 2022. IMA created the Digital Risk Practice in direct response to client needs. “The risks associated with new technologies are growing exponentially, yet products are not keeping up with demand,” said Droege. “IMA is one of few leaders in emerging risks with a unique understanding of the marketplace, making us well equipped to define and provide valuable coverage for the crypto ecosystem.” The Digital Risk Practice is a new division of IMA’s Advanced Industries Specialty, which includes its Technology, Life Sciences and Advanced Manufacturing practice groups. Led by IMA Executive Vice President Mark Ware, the Advanced Industries specialty is a key growth driver for IMA and collectively provides insurance and risk management services to some of the world’s most innovative companies. “Garrett has been at the forefront of IMA’s Web3 efforts and is a pioneer in digital asset risk management,” said Ware. “His unique understanding of the complex insurance marketplace for these innovative companies makes him the ideal leader for IMA’s Digital Risk Practice.” Ruth Rohs, SVP Corporate Communications, Ruth.rohs@imacorp.com Alex Campbell, Center Reach Communication, alexandra@centerreachcommunication.com ### About IMA Financial Group Based in North America, IMA Financial Group Inc. is a leading insurance and risk management broker specializing in emerging risks. Because IMA is employee-owned, its 2,000-plus associates are empowered to provide customized solutions for their clients' unique needs. Contact Details IMA Financial Group Ruth Rohs +1 303-534-4567 ruth.rohs@imacorp.com Center Reach Communications Alexandra Campbell alexandra@centerreachcommunication.com Company Website https://imacorp.com/

February 10, 2023 09:00 AM Eastern Standard Time

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

BioRestorative Therapies, Inc.

By Julian Richard, Benzinga BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application related to its metabolic ThermoStem® program. The Notice of Allowance signals the end of the examination process for the patent application. It indicates that the European Patent Office has determined that the ThermoStem® program is novel, non-obvious, and fully and particularly described in the patent application. The Notice of Allowance is a testament to BioRestorative’s commitment to innovation and advancing medical science through developing novel therapies utilizing adult stem cells. With this milestone, BioRestorative has made significant strides toward achieving its mission of developing and commercializing cell-based products and therapeutics for various metabolic conditions – such as diabetes and obesity – across key international markets. This patent will provide the company with protection for its proprietary ThermoStem® process, which is being developed for the treatment of metabolic syndrome. Metabolic syndrome is a cluster of conditions, such as obesity and increased cholesterol (fat) and glucose in the blood, that increase the risk of type 2 diabetes, heart disease and stroke. The ThermoStem® program harnesses the body’s ability to create new brown fat tissue from human brown adipose-derived stem cells. Pioneering research conducted by Biorestorative Therapies demonstrated that brown tissue burns rather than stores energy. Increased levels of brown tissue support weight loss by increasing metabolism and reducing sugar and fats in the blood. Thus, higher brown fat levels may address metabolic syndrome's significant effects. Obesity management is the subject of intense clinical development with Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the success of Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2 diabetes. “Our patent family for our ThermoStem® program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, CEO of BioRestorative Therapies, commenting on the development. “We are committed to the development of ThermoStem® as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem® developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.” In addition to its metabolic program (ThermoStem®), BioRestorative Therapies is pioneering the use of a patient’s bone marrow cells to treat chronic lower back pain caused by degenerative disc disease. BRTX-100 is currently being evaluated as a non-invasive alternative to surgery in patients with degenerative chronic lower back pain, with results from the clinical study expected in March or April 2023. Visit https://www.biorestorative.com for more information on the company and its product candidates. This article originally appeared on Benzinga here. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

February 10, 2023 08:45 AM Eastern Standard Time

Quantum eMotion Sentry-Q platform to be used in Greybox Solutions digital therapeutics

Quantum eMotion Corp

Quantum eMotion CEO Francis Bellido joins Natalie Stoberman from the Proactive studio to discuss the latest Sentry-Q platform commercial agreement with Greybox Solutions, a Montreal-based health technology company specializing in innovative software development to improve patients' lives. Bellido says this partnership will enable Greybox's TakeCare digital therapeutic product to take advantage of QeM's Quantum-Safe cryptographic platform. Digital therapeutics refers to the use of technology-driven solutions, such as mobile apps, wearable devices, and telemedicine, to enhance patient outcomes by leveraging the benefits of technology such as patient health records convenience, accessibility, and real-time monitoring and feedback. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 10, 2023 08:04 AM Eastern Standard Time

Video

ResolutionRx announces research & development financing agreement with Radium Capital

RespireRx Pharmaceuticals

ResolutionRx Director Arnold Lippa joins Natalie Stoberman from the Proactive studio to discuss its recent letter of intent for financing with Radium Capital. ResolutionRx Ltd is a wholly owned subsidiary of RespireRx Pharmaceuticals. ResolutionRx was formed in Australia on Jan. 11, 2023 by RespireRx as an unlisted public company. RespireRx intends to contribute, sub-license, assign or otherwise make available to ResolutionRx, its cannabinoid drug development program subject to certain liabilities. ResolutionRx would then engage in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 10, 2023 07:56 AM Eastern Standard Time

Video

News Release

Valeo Pharma announces its Onstryv product receives public reimbursement in Quebec

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide). Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 09, 2023 02:03 PM Eastern Standard Time

Video

News Release

Hapbee announces Smart Sleep integration with Oura Ring

Hapbee Technologies Inc

Hapbee CEO Yona Shtern joined Proactive's Steve Darling to share news of an upgrade that combines biometric sleep data gathered from the Oura Ring and the features of Hapbee’s Smart Sleep Pad. Shtern told Proactive the creator of the Oura Ring has granted Hapbee use of its Application Programming Interface for the development of a sleep tracking plus sleep enhancement application. This will now allow the company to provide auto-prompts based on sleep cycles and track users' sleep improvements, he added. Shtern also talked about the feedback the company is hearing from professional athletes regarding its athlete and fitness professional outreach program. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 09, 2023 01:21 PM Eastern Standard Time

Video

New Research Finds Single Dose of Popular Antibiotic Given During Labor Significantly Reduced Risk of Maternal Death or Sepsis in Developing Countries

Society for Maternal-Fetal Medicine

Sepsis — a severe infection in the body that can lead to tissue damage, organ failure, and death — is among the top causes of maternal deaths worldwide, according to the World Health Organization (WHO). It is a life-threatening emergency that is largely preventable with early diagnosis and treatment and may disproportionately affect pregnant people in low- and middle-income countries. WHO has identified reducing maternal deaths, including death from sepsis, as a top global health priority. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™ — and published in the American Journal of Obstetrics & Gynecology — researchers will unveil findings that suggest that a single dose of azithromycin given to women planning a vaginal delivery significantly reduced the risk of maternal death or sepsis. The randomized control trial included 29,278 participants in eight sites of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Global Network for Women’s and Children’s Health Research in Africa (Democratic Republic of Congo, Kenya, and Zambia); Asia (Bangladesh, Pakistan, and two sites in India); and Latin America (Guatemala). Participants were randomized to receive either azithromycin — a popular, low-cost antibiotic used to treat a wide variety of bacterial infections and is on the WHO’s List of Essential Medicines — or a placebo. All participants were at least 28 weeks pregnant with a planned vaginal delivery at a healthcare facility. Overall, 14,590 people received azithromycin and 14,688 received a placebo. All participants were followed for 42 days after delivery, ensuring alignment with the WHO’s definition of maternal mortality, which includes death during pregnancy and within 42 days following delivery. Researchers found that a single dose of azithromycin, given orally, reduced the risk of maternal death or sepsis by 33 percent in women who delivered vaginally. In addition, researchers discovered several secondary findings, including fewer hospital readmissions and emergency visits among patients who received azithromycin. “International organizations identified severe maternal infections leading to death as a major global health problem, especially in developing counties, and there had been little progress over time” says the study’s lead author Alan Thevenet N. Tita, MD, PhD, a maternal-fetal medicine subspecialist at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine, where he holds several positions, including associate dean for Global and Women’s Health; Mary Heersink Endowed Chair of Global Health and Director of the Global Health Institute; and director of the university-wide interdisciplinary Center for Women’s Reproductive Health. “We wanted to alleviate the burden of maternal infections in populations that give birth predominantly vaginally. Our research shows that just one dose of azithromycin may be a useful, low-cost intervention to reduce sepsis and attendant maternal deaths.” The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Foundation for the National Institutes for Health (through a grant from the Gates Foundation). The complete study is also being published simultaneously in the New England Journal of Medicine today. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for maternal-fetal medicine subspecialists, who are obstetricians with additional training in high-risk pregnancies. SMFM represents more than 5,500 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to advance optimal and equitable perinatal outcomes for all people who desire and experience pregnancy. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2023 Annual Meeting news and updates, follow the hashtag #smfm23. Contact Details Addis Communications Karen Addis +1 301-787-2394 karen@addispr.com Society for Maternal-Fetal Medicine Kerri Wade +1 202-236-1780 kwade@smfm.org Company Website https://www.smfm.org/

February 09, 2023 10:15 AM Pacific Standard Time

1 ... 121 122 123 124 125 ... 227